FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:FLX Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11077
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate the cancer. The company has advanced into the clinic a dual-inhibitor drug that target FLT3 and CDK4 and 6 for the treatment of cancer. FLX Bio is headquartered in South San Francisco, California, the US.

FLX Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
Partnerships 14
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
Licensing Agreements 16
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc – Key Competitors 17
FLX Bio Inc – Key Employees 18
FLX Bio Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Feb 05, 2018: FLX Bio Names Michael Giordano As Board Director 20
Jan 03, 2018: FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology 21
May 31, 2017: FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board 22
Clinical Trials 23
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate 23
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
FLX Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc, Key Competitors 17
FLX Bio Inc, Key Employees 18

List of Figures
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nucor Corporation:戦略・SWOT・企業財務分析
    Nucor Corporation - Strategy, SWOT and Corporate Finance Report Summary Nucor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • TOLMAR Inc-製薬・医療分野:企業M&A・提携分析
    Summary TOLMAR Inc (TOLMAR), a subsidiary of Tolmar Holding Inc is a developer, manufacturer and distributor of pharmaceutical products. The company provides generic dermatology products such as creams, gels, ointments and solutions. It also provides levetiracetam oral solutions including antiepilep …
  • TriVascular Inc:製品パイプライン分析
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …
  • The Scotts Miracle-Gro Company:企業の戦略・SWOT・財務分析
    The Scotts Miracle-Gro Company - Strategy, SWOT and Corporate Finance Report Summary The Scotts Miracle-Gro Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Forestar Group Inc:企業の戦略・SWOT・財務分析
    Forestar Group Inc - Strategy, SWOT and Corporate Finance Report Summary Forestar Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mallinckrodt LLC:医療機器:M&Aディール及び事業提携情報
    Summary Mallinckrodt LLC (Mallinckrodt), formerly Therakos Inc, a subsidiary of Mallinckrodt Plc, is a provider of autologous immune cell therapy through extracorporeal photopheresis. The company provides Therakos Cellex Photopheresis system, which is indicated for use in ultraviolet-A irradiation i …
  • CPFL Energia SA:発電所・企業SWOT分析
    CPFL Energia SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • Hays plc:企業の戦略・SWOT・財務分析
    Hays plc - Strategy, SWOT and Corporate Finance Report Summary Hays plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Krystal Biotech Inc (KRYS):製薬・医療:M&Aディール及び事業提携情報
    Summary Krystal Biotech Inc (Krystal Biotech) is a drug development company that uses gene therapy to develop novel treatments for skin diseases. The company’s pipeline products include KB103, KB105, and KB200. Its products are used for the treatment of dystrophic EB, TGM1-deficient autosomal recess …
  • OBI Pharma Inc (4174)-医療機器分野:企業M&A・提携分析
    Summary OBI Pharma Inc (OBI Pharma) is a developer of therapies for the treatment of cancer and infectious diseases. The company develops its pipeline products through its carbohydrate synthesis discovery platform. Its flagship products include OBI-822, an active immunotherapy which is intended for …
  • Jardine Cycle & Carriage Limited:企業の戦略・SWOT・財務分析
    Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Genesee & Wyoming Inc.:企業のM&A・事業提携・投資動向
    Genesee & Wyoming Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Genesee & Wyoming Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Naspers Limited:企業の戦略・SWOT・財務分析
    Naspers Limited - Strategy, SWOT and Corporate Finance Report Summary Naspers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the ope …
  • Sasol Ltd (SOL):企業の財務・戦略的SWOT分析
    Sasol Ltd (SOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Diagnostic & Therapeutic Center of Athens Hygeia SA (HYGEIA):企業の財務・戦略的SWOT分析
    Diagnostic & Therapeutic Center of Athens Hygeia SA (HYGEIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the com …
  • JW Pharmaceutical Corp (001060):製薬・医療:M&Aディール及び事業提携情報
    Summary JW Pharmaceutical Corp (JW Pharmaceutical), a subsidiary of JW Holdings Corp is a provider of generic drugs. The company develops and markets analgesics, antipyretics and cold remedy, antidote agents, antimicrobials, anticancer agents, and others. It offers multivitamins and antianemic agent …
  • ConocoPhillips (COP):石油・ガス:M&Aディール及び事業提携情報
    Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liquids across the world. It has assets across North America, Europe, Asia and Australia. Its ass …
  • Cox & Kings Limited:企業の戦略・SWOT・財務分析
    Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report Summary Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Triumph Group Inc:企業の戦略・SWOT・財務情報
    Triumph Group Inc - Strategy, SWOT and Corporate Finance Report Summary Triumph Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆